UK markets closed

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
119.04-0.40 (-0.33%)
At close: 4:00PM EDT
Sign in to post a message.
  • P
    Patrick S
    This is probably a good entry point or avg down for the longs. Accumulation shift off the $113 support level bounce & MACD crossover. Per the 1-month chart it would appear the worst is over. Expecting a run within the next few trading days. Look for break of $117 with support and then we're back into 120's by August.
  • R
    RJ
    This is your chance to get in
  • M
    M
    $GH.TO conversation
    AGLC open for business. Alberta open for business. I think Gamehost earnings will surprise to the upside over next 24 months. Then bake in their share buybacks and cost reductions, even lower corporate tax; you get recipe for strong upside after velocity of gross revenues and their EBITDA take hold. $12 may be the new baseline for these shares on the TSX. $GH
  • R
    RH
    Announcement of earnings date -hedge funds stepped up and are betting on a disappointment
  • C
    Chris
    Guardiant Health is being added to the My Animo Stock Portfolio Monday. Must see good things in the August quarterly report. https://youtu.be/jtKZgsodKgM
  • j
    jim
    Don't expect miracle for GH, like I told you guys before it will back and and forth for GH at least through October. The best thing that can happen with GH is for a big pharma to offer them the magic $170 per share that the two boys are looking for at this time. Eight months ago, things were different but now you can tell the level of competence at all the areas of this organization is just not there.
    You can still keep this stock but don't expect miracle...The SWAV on the other hand, has a great team and I can tell you that my estimate for this company now is $250 in six months.
    I am sure those insiders will give me the thumbs down but I know them better!!
  • B
    Bull Market Mentality
    This will be a $1000 this decade , probably midway into it glta, what a great cause
  • F
    Frank
    Day traders favorite stocks
  • F
    Frank
    What’s happening?keep downward
  • J
    JoeSchmo
    Some good news this morning from CFRA:

    We initiate coverage on Guardant Health (GH) with a Buy rating and a price target of $165, as we see incredible long-term potential for GH in the market for blood-based cancer tests, which may be underappreciated. A key pipeline asset for GH is its LUNAR-2 test, which is intended for colorectal cancer (CRC) screening in asymptomatic individuals of average risk, a $20 billion opportunity in the U.S. By 2023, we expect the LUNAR-2 test to be the first approved liquid biopsy for CRC, offering significant convenience over current CRC screening options (e.g., colonoscopies). Key risks to our recommendation include pipeline setbacks, delays in obtaining expanded third party payer coverage and reimbursement, and increased competition. Although we expect the company to face immense competition in the long-term and be unprofitable over the next several years, we believe that GH will maintain its leadership position in the large liquid biopsy market over the next few decades.
  • F
    Frank
    What’s happening?
  • R
    RH
    If GH were to partner with SAVA on their new early stage blood based test for Alzheimers BOTH companies and their shareholders would benefit big time.
    Cassava Science's SavaDx is an investigational diagnostic
    candidate to detect Alzheimer’s with a simple blood test.
  • R
    RH
    Any need to account for today’s pullback back??
  • J
    Joe
    I see this more as a defensive action against Roche/Foundation. Not a gamechanger.
    "New Guardant360 TissueNext™ tissue biopsy test is now available for ordering alongside the Guardant360® CDx blood test, providing oncologists an efficient “blood-first, tissue-next” approach for complete genomic testing."
  • F
    Frank
    Time to get out?
  • K
    Kevin
    ready to bounce back to $170 and this time it will go to $200. Classic chart and technical formation.
  • F
    Frank
    @Lee thanks for the GH cofounder interview. Have a better understanding of GH and biotech as a whole
  • d
    dillois
    Hope nobody here was scared out of their shares yesterday. Took the opportunity to buy a bit more on the drop (side bet) and sold those today.
  • d
    dillois
    Love it when GH starts it's run at off the base of the next upward cycle! It's like the weeks leading up to Christmas.
  • J
    Joe
    Labcorp Launches Companion Diagnostic for Amgen’s Newly-approved Lung Cancer Therapy.

    Collaboration with Qiagen. No biggie imo. QGEN is located in the Netherlands. LH will play catch-up.